In Vitro and In Vivo Antimalarial Activities of T-2307, a Novel Arylamidine
In Vitro and In Vivo Antimalarial Activities of T-2307, a Novel Arylamidine
复制标题
DOI：
10.1128/aac.05856-11
复制
发表时间：
2012-04-01
影响因子：
4.9
通讯作者：
Kawazu, Shin-ichiro
中科院分区：
文献类型：
--
作者：
Kimura, Akiko;Nishikawa, Hiroshi;Kawazu, Shin-ichiro
T-2307是一种新型的芳香脒类化合物，具有广谱抗真菌活性。在这里，我们评估了T-2307的体外和体内抗疟活性。T-2307对疟原虫FCR-3和K-1株的50%抑制浓度（IC（50）s）分别为0.47和0.17 μ M。在啮齿类动物疟疾模型中，2.5 - 10 mg/kg体重/天剂量的T-2307显示出抗血液期和肝脏期寄生虫的活性。总之，T-2307表现出体外和体内抗疟活性。
T-2307, a novel arylamidine, has been shown to exhibit broad-spectrum antifungal activities against clinically significant pathogens. Here, we evaluated the in vitro and in vivo antimalarial activity of T-2307. The 50% inhibitory concentrations (IC(50)s) of T-2307 against Plasmodium fakiparum FCR-3 and K-1 strains were 0.47 and 0.17 mu M, respectively. T-2307 at 2.5 to 10 mg/kg of body weight/day exhibited activity against blood stage and liver stage parasites in rodent malaria models. In conclusion, T-2307 exhibited in vitro and in vivo antimalarial activity.